Aktuellt
SENASTE
Redeye leaves a comment on Coegin Pharma’s announcement of having secured an exclusive agreement with the University of Bradford to acquire the commercial rights to a pioneering patented technology platform with pigmentation peptides. With a possible launch of products already by 2026, we see great potential to expand its cosmetic product offering and increase shareholder value.
LÄS MER
